Cosmos Health Inc. (COSM) stock
COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30107% above fair value
$2.85+0.36 (+14.46%)
Close on Nov 17, 2026Market cap $286.81MP/E –Yield –
Cosmos Health r&d expenses
Research and development expenses are spending on new products and technology.
Cosmos Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $497.65K, down 20.2% year over year. For fiscal 2025 it was $519.36K, down 2.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $519.36K | -2.6% |
| FY2024 | Dec 31, 2024 | $533.29K | +223.5% |
| FY2023 | Dec 31, 2023 | $164.86K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $68.55K | -8.2% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $410.76K | -23.0% |
| Q3 FY2025 | Sep 30, 2025 | $18.34K | – |
| Q2 FY2025 | Jun 30, 2025 | $74.64K | – |
| Q1 FY2025 | Mar 31, 2025 | $15.63K | – |
| Q4 FY2024 | Dec 31, 2024 | $533.29K | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
See a number that looks wrong?